Osmol Therapeutics Initiates IND Enabling Studies to Develop First Therapy for Prevention of Chemotherapy-Induced Peripheral Neuropathy
Retrieved on:
Thursday, May 13, 2021
Oncology, Health, Other Health, General Health, Pharmaceutical, Biotechnology, Clinical medicine, Medicine, Cancer, Chemotherapy, Oncology, Chemotherapy-induced peripheral neuropathy, Taxane, Breast cancer, Causes of cancer pain, OSM-0205 and CIPN, Osmol Therapeutics, OSM-0205 AND CIPN, OSMOL THERAPEUTICS
b'Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN).
Key Points:
- b'Osmol Therapeutics today announced that it has initiated Investigational New Drug (IND) enabling studies to develop a therapy to prevent chemotherapy-induced peripheral neuropathy (CIPN).
- OSM-0205\xe2\x80\x99s mechanism addresses the off-target toxicity of microtubule-based chemotherapy agents that results in a calcium surge leading to CIPN.
- Taxanes are the most widely used chemotherapy treatment for breast cancer and can lead to CIPN in up to 80% of patients.
- The company\xe2\x80\x99s lead indication will be for the prevention of CIPN in breast cancer patients treated with taxane-based therapy, a treatment regimen in which up to 80% of patients experience CIPN.